<DOC>
	<DOC>NCT02852850</DOC>
	<brief_summary>Molecular imaging with infliximab antibody with FITC has the potential to predict therapeutic responses to infliximab antibody and can be used for personalized medicine in ulcerative colitis.</brief_summary>
	<brief_title>In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients with active ulcerative colitis will receive infliximab antibody therapy. Patients with impaired blood clotting. Patients with short bowel syndrome. Patients during the pregnancy and lactation period. Patients received enema therapy within 1 month before inclusion in the study, or had antiTNF therapy within the last 12 months. Patients participated in another clinical trial or administrated other investigational drugs within 4 months prior to the screening visit. Patients with moderate to severe heart failure, active tuberculosis or acute infections.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>